Meeting Banner
Abstract #2167

Potentiation of the Metabotropic Glutamate Receptor Subtype 5 Modulates Dopaminergic Neurotransmission

Nellie Byun1, 2, Ayan Ghoshal, 13, Nathaniel D. Kelm2, 4, Robert L. Barry2, 5, Wellington Pham2, 5, Carrie K. Jones1, 3, John C. Gore2, 5, P. Jeffrey Conn1, 3

1Vanderbilt Center for Neuroscience Drug Discovery, Nashville, TN, United States; 2Vanderbilt University Institute of Imaging Science, Nashville, TN, United States; 3Pharmacology, Vanderbilt University Medical Center, Nashville, TN, United States; 4Biomedical Engineering, Vanderbilt University, Nashville, TN, United States; 5Radiology & Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, United States

Previous preclinical studies have demonstrated the potential of compounds that target the metabotropic glutamate receptor subtype 5 (mGluR5) for the treatment of schizophrenia. Like typical and atypical antipsychotic drugs, the novel selective mGluR5 potentiator VU0360172 suppressed amphetamine-induced hyperlocomotion in rodents. Here we used VU0360172 and pharmacologic MRI (phMRI) to determine specific regions of mGluR5-mediated modulation of amphetamine-induced brain activation as well as the effects of VU0360172 alone.